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doi:10.1016/j.jfma.2011.01.007Background/Purpose: The intermediate course of schizophrenia is a complex intertwined with
the heterogeneity of the illness. This article attempts to simplify this complexity using a hypo-
thetical tripartite based on the profile of symptoms at 6 months after acute treatment.
Methods: This is a prospective 5-year follow-up study including 163 schizophrenic inpatients in
northern Taiwan comparing patients’ demographic data at index admission, scores on the Posi-
tive and Negative Syndrome Scale (PANSS) for schizophrenia and social function scale
measured at admission, 6-month follow-up, and annually, and scores on a neuropsychologic
test battery measured approximately 5 years after recruitment.
Results: Patients were grouped into three subtypes based on their sixth-month symptom-
atology by Generalized Association Plots, designated as remitted (RM), persistent delusion/
hallucination (PDH), and markedly blunting (MB) groups. These three subtypes presented with
similar positive symptom profiles at recruitment, yet during follow-up, the PDH group tended
to maintain the highest risk of having worse clinical symptomatology, social functioning, and
neuropsychologic functioning, and the RM was the best outcome group.t of Psychiatry, National Taiwan University Hospital and College of Medicine, National Taiwan
ad, Taipei 10043, Taiwan.
.tw (H.-G. Hwu).
ight ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
266 C.-C. Liu et al.Conclusion: This three-subtype model provides a practical reference to predict medium-term
outcomes by the subject’s response to acute treatment and serves as a model to sort out part
of the heterogeneous nature of schizophrenia that still should be examined by further psycho-
pharmacological, neurobiological, and genetic studies.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
The course and outcome of schizophrenia are hard to
predict despite long-term study.1e3 Researchers tried to
examine clinical and psychosocial variables to yield better
prognostic power for course and outcomes,4e6 or attemp-
ted to classify subtypes of schizophrenia according to
outcome and severity.7,8 The heterogeneity of the clinical
entity, the differences in diagnostic criteria, treatment
modalities, and the stage of illness, the measurement of
clinical severity and outcomes, and the differential
outcomes between the dropouts and the follow-up groups
all contribute to the inconclusiveness.9 Studies require
broad symptom profiles to characterize the courses of
schizophrenia and to better understand its intermediate
course.10
The timing of symptom assessment is important for
subtyping of schizophrenia. In our previous study, we used
a new technique, the generalized association plot (GAP)
analysis,11 to subtype schizophrenia based on symptom
profiles at the time of admission and stratified a group with
negative symptoms and the other without marked negative
symptoms.12 However, the florid psychotic symptoms at
admission usually regress somewhat after treatment and
therefore do not provide enough information about long-
term outcome,9 and a substantial proportion of patients
in the subgroups with acute symptoms would be catego-
rized into other subgroups when symptoms are not acute.13
Symptomatology at discharge from the hospital is also
a poor predictor because the time of discharge is biased by
service availability.14 Although the nature of schizophrenia
subtypes and their correlations to outcomes are com-
plex,12,15e17 the symptom profile assessed 3 to 6 months
after acute treatment was a better reference to predict
future course and outcome.18,19 In the current study, we
attempt to depict the 2- to 5-years course and outcomes of
schizophrenia in terms of clinical symptom profile, social
functioning, and neurocognitive functioning, using the
subtypes identified by GAP analyses of symptomatology 6
months after acute treatment. We also examine whether
this subtyping approach can reciprocally differentiate
clinical variables at recruitment.
Methods
Participants
Participants were schizophrenic patients in northern
Taiwan who have been followed annually for up to 5 years
in the Multidimensional Psychopathological Group Research
Project from August 1993 to June 1998. The recruitment
procedures have been described in detail in earlier reportsof this project.12,20 Briefly, all patients met the criteria for
schizophrenia set forth by the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Revision (DSM-IV,
American Psychiatric Association, 1994) and were consec-
utively admitted to the acute wards of three hospitals,
National Taiwan University Hospital and the university-
affiliated Taipei City Psychiatric Center and Taoyuan
Psychiatric Center with written informed consent. All
participants received a standard set of clinical manage-
ment, including psychopharmacologic treatment, family
and psychosocial intervention, and occupational therapy.
The diagnoses were confirmed at discharge by consensus
among three senior psychiatrists using data available from
the Chinese version of the Diagnostic Interview for Genetic
Study (DIGS),21 clinical observations, medical records, and
key informants.
A total of 225 patients completed a Mandarin version
of the Positive and Negative Syndrome Scale (PANSS) for
schizophrenia assessments at admission and were recruited.
Of these patients, 181 were reassessed at 6-month follow-
up, 172 at 1-year, 156 at 2-year, 133 at 3-year, 149 at 4-year,
and 100 at 5-year follow-ups, respectively. The 163 patients
with complete PANSS data at recruitment and at 6months
were subtyped based on 6-month PANSS scores.
Measurements
Patients were assessed by PANSS; a clinical data book
recording the participants’ demographic features, previous
psychiatric history, treatment history, and social func-
tioning; and a neuropsychologic test battery composed of
Continuous Performance Test (CPT), the Wisconsin Card
Sorting Test (WCST), the Mandarin version of the Wechsler
Adult Intelligence Scale-Revised (WAIS-R), Trail Making
Test, and the Wechsler Memory Scale-Revised (WMS-R).
These tools have been applied in our previous studies with
good reliability.12,21e23
Demographic and clinical variables used for analyses
included age at recruitment, sex, years of education,
employment status at recruitment, age at onset of initial
nonspecific symptoms, age at onset of psychotic symptoms,
age at onset of severe function impairment, mode of onset,
duration of illness from onset of any psychotic symptom
to the index admission of the study, length of stay for the
index admission, and the highest antipsychotic dosage
converted to chlorpromazine equivalent dosage (CPZE;
mg/day) of the index admission and at discharge. Patients’
social functioning was measured using a seven-point Likert
scale to evaluate four dimensions in their daily lives:
interpersonal relationships, achievements, time arrange-
ment of daily activities, and family-life functioning.24
Individual subtests of the neuropsychologic tests were
recategorized into constructs of eight cognitive functional
Schizophrenia course by a three-subtype model 267domains that hypothetically reflect basic cognitive processes
following the Kremen method.25 These domains comprised
verbal-conception, visual spatial ability, abstraction/execu-
tion, verbal memory, visual memory, perceptual-motor
ability, mental control, and attention. Scores in each cate-
gory were transformed into Z-scores comparedwith a control
group matched for age, sex, and education years were
indicative of patients’ neuropsychologic functioning.22
Outcomes were indicated by annual repeated measure-
ments of PANSS scores and social functioning during the
next 5 years, and one-shot neuropsychologic functioning
measured at the time point close to the fifth year of
follow-up.
Subtyping of participants and delineation of
symptom dimensions
We used Generalized Association Plots (GAP)26 to stratify
patients into subtypes based on their PANSS scores 6 months
after recruitment. Briefly, the raw PANSS data matrices for
163 patients with 33 symptoms were permuted and dis-
played as a color data matrix map (Fig. 1). In the left lower
plot, each PANSS symptom score of every patient is shown
as a color dot. A rainbow spectrum (blue to red) is adopted
to represent the severity rating (1 to 7) of the specific
symptoms in each study subject. Each row-strip in this map
represents an individual patient’s symptom profile. Each
column-strip behaves as a histogram for that particular
symptom across all patients. The global interaction pattern
of each patient-cluster in every symptom-group can then
be seen. The patients were then clustered into subtypes
based on the proximity of their symptom profiles.
The progressive change in severity of symptom dimen-
sions were also analyzed using the GAP to obtain the
structure of symptom dimensions. We identified the items
comprising each symptom dimension at every assessment
during the first 2 years, and then defined the core symptom
items of each dimension (Table 1) to be used as indicators
of symptomatic outcome in follow-up assessments.
Statistical analyses
The differences in patients’ demographics and symptom-
atology at admission among clinical subtypes were exam-
ined by the chi-square test for categoric variables and by
the analysis of variance (ANOVA) for continuous variables.
Changes of repeated measurements of PANSS scores and
social functioning during follow-up were evaluated.
Because the distributions of scores in all five symptom
dimensions were prominently skewed, the ratings were
dichotomized by the median of each dimension score over
the course of 5-year follow-up at higher score or lower
score level. Not all participants were evaluated at each
follow-up; therefore, we first used data of the 163 patients
during the first 2 years’ follow-up in which 96 of them (59%)
completed PANSS assessments at all four time points
(baseline, 6 months, 1 year, and 2 years) to avoid potential
bias introduced by informative dropouts considering the
high attrition rate in the total length of 5-year follow-up
(dropouts 26%; intermittent missing values 56%). These 2-
year completers had a baseline PANSS profile similar tothat of those who did not complete PANSS assessment at all
time points (data not presented).
The mean PANSS profiles for the three subtypes were
estimated using the mixed-effect normal regression model.
The Bayesian information criterion (BIC) index based on
restricted-maximum-likelihood estimation27 was used for
model selection, which included examinations of the
heterogeneity between study subjects (random-effect vs.
fixed-effect models) and the selection of appropriate
covariance structure between observations due to repeated
measurements by time and possible variations among the
three subtypes. The covariates in the initial regression
models were subtype and time indicators. With F-test
p > 0.05 for exclusion, the stepwise backward elimination
was performed to determine the most parsimonious
models, which will later be referred to as the final models.
We then fit the logistic model using the generalized
estimating equation (GEE)-based robust procedure to
consider the correlations over follow-up time points within
each individual to yield estimates regarding to what extent
the 6-month subtype can predict clinical symptom severity
across the span of 5 years based on all data available at
each follow-up.28 The working correlation in the GEE was
set to be the first-order autoregressive structure.
The GEE logistic regression model was also used for
estimating social functioning during the 2-year (132, 144,
and 141 of the 163 patients assessed at 6 months, 1 year, and
2 years, respectively) and the 5-year follow-up periods to
account for within-subject correlations among repeated
measurements over time. The social functioning was
dichotomized by high (> 3) and low (3 or less) scores as
adequate and inadequate in each dimension for analytical
purposes. We used the probability of high score at each time
point to represent the average profile of social functioning
for each subtype in the first 2-year follow-up. Covariates
included in the initial models for social functioning were
subtype and time indicators. Similar backward elimination
procedures were performed for covariate selections.
The neuropsychologic functioning assessed at the fifth-
year follow-up was tested by the ANOVA and the analysis of
covariance (ANCOVA) to examine differences among the
three subtypes.
Results
Table 2 shows the demographics and clinical profiles of the
163 patients.
Subtypes of schizophrenia using GAP analysis
GAP analysis of PANSS profiles at 6-month follow-up
revealed three distinct subtypes of patients (Fig. 1). In the
upper part of the figure, the “symptoms versus patient
plot”, the raw scores of all symptoms are generally very low
(blue). This group of 61 patients (37.4%) was designated as
the remitted subtype (RM). Right below the RM, a group of
14 patients with obvious (yellow and red) delusion/halluci-
nation symptoms is assigned to the first persistent delusion/
hallucination subtype (PDH1). The middle portion of the
figure represents another group of 50 patients (30.7%) only
having relatively high negative symptom scores (yellow and
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Figure 1 Generalized association plots of the 6-month PANSS data. The left lower part of the generalized association plot is the
symptom versus patient plot. Each PANSS symptom score of every patient is shown as a color dot. A rainbow spectrum (blue to red) is
adopted to represent the severity rating (1 to 7) of the specific symptoms in each study subject. Each row-strip in this map represents
an individual patient’s symptom profile. Each column-strip acts as a histogram for that particular symptom across all patients. RM:
the remitted subtype, most symptom scores are very low (blue color) after treatment at 6-month follow-up; PDH1: the first part of
persistent delusion/hallucination subtype, presenting only significant (coded in yellow and red) delusion/hallucination symptoms;
MB: the markedly blunting subtype, having very low scores in the delusion/hallucination, hostility/excitement, and disorganization
dimensions yet relatively high negative symptom scores (yellow and red); PDH2: the second part of persistent delusion/hallucination
subtype, having marked severity (red color) in all five, including delusion/hallucination, symptom dimensions; the two groups with
persistent delusion/hallucination symptoms, PDH1 and PDH2, are combined into a single subtype PDH.
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Table 1 Core symptom items of each symptom dimensions.a
Negative symptoms Disorganized thoughts Hostility/excitement Delusion/hallucination Anxiety/depression
Blunted effect Conceptual
disorganization
Excitement Delusions Anxiety
Emotional withdrawal Stereotyped thinking Hostility Hallucinatory behavior Guilt feelings
Poor rapport Poor attention Uncooperativeness Suspiciousness/
persecution
Depression
Motor retardation Preoccupation Poor impulse control
Passive/apathetic
social withdrawal
Anger
Lack of spontaneity and
flow of conversation
Difficulty in delaying
gratification
Disturbance of volition Affective lability
a Items not consistently presenting in the same symptom dimensions across the follow-up are grandiosity, difficulty in abstract
thinking, somatic concern, tension, mannerism and posturing, unusual thought content, disorientation, lack of judgment and insight,
and active social avoidance. The sums of the core symptom items in each symptom dimension across all assessment time points generally
revealed high correlations to the sums of the composition items in each symptom dimension at a specific time point, with Pearson
coefficients approximately 0.9 to 1.
Schizophrenia course by a three-subtype model 269red) was assigned to the markedly blunting subtype (MB).
The bottom of the figure represents a group of 38 patients
with marked severity (red) in all five symptom dimensions
called the second persistent delusion/hallucination subtype
(PDH2). The PDH1 and PDH2 were combined into one
subtype, PDH (nZ 52; 31.9%), for further analyses.Comparison of clinical variables at recruitment
Table 2 shows the differences in clinical profiles at
recruitment among the three subtypes. By the time ofTable 2 Differences of demographics and symptom profile at r
All patients (N Z 163)
Age at recruitment 30.4 (7.3)
Age at onset of initial symptoms 21.2 (6.4)
Age at onset of psychotic symptoms 22.5 (6.5)
Age at onset of severe symptoms 23.3 (6.8)
Mode of onset (acute/nonacute) 91/72
First admission/multiple admission 62/101
Duration of illness (years) 7.9 (5.6)
Sex (male/female) 89/74
Education (years) 11.4 (2.8)
Single/married 121/42
Employed/unemployed 83/80
Negative symptom (at admission) 19.7 (9.0)
Disorganized thoughts (at admission) 11.4 (5.2)
Excitement/hostility (at admission) 16.4 (8.8)
Delusion/hallucination (at admission) 13.2 (3.6)
Anxiety/depression (at admission) 6.0 (2.6)
Length of stay (index admission) 64.9 (45)
Highest CPZE used (mg/day) 906 (774)
CPZE used at discharge (mg/day) 554 (538)
CPZE Z Chlorpromazine equivalent dosage; MB Z markedly bluntin
RM Z remitted subtype.
* Data were presented as mean (standard deviation) for continuous
used for examining differences among continuous variables. Chi-squa
ables. Acute onset was defined as the duration between onset of any
than 1 year.admission, patients in the PDH group had the earliest age of
onset of nonspecific and psychotic symptoms and the
patients in the MB group had significantly higher scores in
the negative symptoms; otherwise the distributions of
demographic characters and symptoms in the other four
dimensions were not significantly different among three
subtypes. During hospitalization, the RM group had the
shortest length of stay of the index admission (mean of 54
days), marginally different (p Z 0.053) from the other two
subtypes (71 and 72 in the PDH and MB groups, respec-
tively). The highest dose of antipsychotic agent was
significantly lower in the RM group (mean CPZE 733 mg/day)ecruitment among the three 6-month subtypes.*
RM (N Z 61) PDH (N Z 52) MB (N Z 50) p value
31.4 (7.7) 28.4 (6.5) 31.1 (7.5) 0.07
22.5 (7.4) 19.2 (4.6) 21.6 (6.3) 0.02
23.8 (7.4) 20.5 (5.3) 23.1 (6.1) 0.02
24.4 (7.5) 21.4 (5.6) 24.1 (6.7) 0.04
33/28 30/22 28/22 0.93
23/38 19/33 20/30 0.94
7.6 (5.4) 7.9 (5.4) 8.1 (5.9) 0.09
35/26 31/21 23/27 0.33
11.8 (3.1) 10.9 (2.1) 11.4 (3.1) 0.28
41/20 43/9 37/13 0.17
35/26 20/32 28/22 0.09
16.8 (10.8) 18.8 (8.7) 24.0 (9.5) 0.0001
10.8 (5.3) 11.1 (5.0) 12.6 (5.2) 0.18
16.0 (8.7) 15.7 (8.0) 17.7 (9.7) 0.47
13.1 (3.3) 13.6 (3.2) 12.9 (4.3) 0.55
5.8 (2.5) 5.5 (2.2) 6.6 (3.0) 0.10
53.9 (34.1) 70.8 (49.5) 72.1 (49.8) 0.053
733 (486) 1094 (850) 922 (942) 0.046
473 (399) 567 (560) 641 (647) 0.26
g subtype; PDH Z persistent delusional/hallucination subtype;
variables and n1/n2 for binary variables. Analysis of variance was
re test was used for examining differences among category vari-
initial symptom and onset of any psychotic symptom being less
270 C.-C. Liu et al.than in the other two subtypes (1094 and 922 in the PDH
and MB groups, respectively; p Z 0.046). The mean CPZEs
at discharge of the index admission were similar among
groups.
The 6-month subtype and symptomatology during
follow-up
The trends of longitudinal symptom profile were first
analyzed using the 96 participants who completed follow-
up PANSS in the first 2 years. The estimated mean profiles in
the length of 2-year follow-up were obtained using
parameter estimates from the final mixed-effect regression
model for each symptom dimension (Fig. 2). Statistically,
the patients with PDH showed significantly higher scores
than those in the RM group in negative symptoms (mean
score difference over all follow-up 4.18; 95% confidence
interval (CI): 2.17 w 6.18), disorganized thoughts (3.34;
95% CI: 1.99w 4.70), and delusion/hallucination (4.08; 95%
CI: 2.91 w 5.25). The MB group had higher scores than the
RM group in negative symptoms (7.78; 95% CI: 5.93w 9.63)
and disorganized thoughts (2.73; 95% CI: 1.31w 4.14). The
MB group had higher scores than the PDH group in negative
symptoms (3.6; 95% CI: 1.75 w 5.45), yet had lower scores
in the dimension of delusion/hallucination (2.74; 95% CI:
1.57 w 3.92).
Estimations of the GEE logistic model using 5-year data
suggest similar trends found by the 2-year analyses.
Patients in the PDH group were more likely to be rated at
the higher end of the delusion/hallucination (odds Ratio
(OR) 5.72; 95% CI 3.2w10.3), disorganized thought (OR
5.16; 95% CI 2.8w9.5), and negative symptoms (OR: 2.85;
95% CI: 1.6w5.1) compared with the RM group. Patients in
the MB group were more likely to be at the higher end of
negative symptoms (OR 5.5; 95% CI 3.0w10.1) and disor-
ganized thought (OR 2.7; 95% CI 1.4w5.0) compared with
the RM group. Yet, the MB and RM groups did not differ
significantly in the other three symptom dimensions. The
MB group had more severe negative symptoms than the PDH
group (OR 1.94; 95% CI 1.1w3.5), whereas the PDH group
had more severe delusion/hallucination (OR 4.25; 95% CIN
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GEE logistic regression analyses with multiple predictors
revealed that the differences among these three subtypes
persisted, after adjusting for factors known to affect the
course and outcomes of schizophrenic patients, including
age at recruitment, age at onset of initial symptoms, mode
of onset, duration of illness, sex, education, marital status,
and employment status (data not presented).
The 6-month subtype and social functioning during
follow-up
The profile of four social functioning dimensions among
three subtypes was first done by estimating proportions of
participants reporting with adequate social functioning
among three subtypes during the course of the 2-year
follow-up (Fig. 3). The log ORs with GEE estimates of
empirically adjusted standard errors for each dimension
were calculated to determine if there were significant
differences among subtypes. The RM group was more likely
to have better interpersonal relationships (OR 4.04; 95% CI
2.24 w 7.27), achievement (OR 3.72; 95% CI 1.97 w 7.02),
time arrangement (OR 4.21; 95% CI 2.30w 7.72), and family
life (OR 3.85; 95% CI 2.07 w 7.06) than the PDH group over
all the time points. The MB group did not show differences in
interpersonal relationship and family life compared with the
PDH group at recruitment, but were more likely to have
better social functioning after the end of the first-year
follow-up (interpersonal relationship: OR 2.72; 95% CI
1.33w 5.59; family life: OR 3.24; 95%CI 1.62w 6.47). TheMB
group was more likely to have better achievement (OR 2.35,
95% CI 1.23w 4.51) and time arrangement (OR 2.32, 95% CI
1.23w 4.35) than the PDH group over all the time points. The
RM group only had persistent significantly better time
arrangement (OR1.82, 95%CI 1.01w 3.26) than theMBgroup.
Again, the estimations using 5-year data suggest similar
trends. The PDH group was most likely to have poorer social
functioning compared with the other subtypes, whereas the
MB group was also more likely to have poorer social func-
tioning than the RM group.1Y 2Y
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Figure 3 Comparison of estimated adequate social functioning among three subtypes according to (A) interpersonal relationship,
(B) achievement, (C) time arrangement, and (D) family life. The estimated probability of high (scoring >3) social functioning with
plus and minus one standard error for the remitted subtype (bolded solid line), the markedly blunting subtype (solid line), and the
persistent delusion/hallucination subtype (dashed line).
Schizophrenia course by a three-subtype model 271The 6-month subtype and neuropsychologic
functioning
Table 3 shows p values of the Z-scores in the ANOVA for
each of the eight indicators of neuropsychologic func-
tioning. In general, all patients revealed significantly
impaired performance in all measured parameters
compared with the general population. Among the three
subtypes, patients showed significant differences in visual
spatial ability, verbal memory, visual memory, and mental
control, yet no differences in the other four domains. The
post hoc tests between pairs of subtypes revealed that the
differences came mainly from the inferior performance of
the PDH group in each category, whereas no significant
differences were shown between the RM and the MB
groups. The aforementioned differences in neuro-
psychologic functioning between the PDH group and the
other two subtypes were still seen after adjusting for age,
education, and duration of illness by the ANCOVA (data not
presented).
Discussion
Based on the PANSS data assessed 6 months after acute
treatment, we categorized a cohort of 163 patients withDSM-IV schizophrenia by the GAP method into three
subtypes: RM, PDH, and MB. We thought this model would
offer a practical approach to delineate the medium-term
course of schizophrenia. The analyses either by using the 2-
year complete follow-up data or the 5-year data with all
available information demonstrate a clear pattern of
differences among these three subtypes of schizophrenia
with regard to clinical profiles, social functioning, and
neurocognitive functioning during follow-up.
Various approaches have been adopted to search for
homogenous subtypes.8,29 Either paranoid versus non-
paranoid subtype30,31 or deficit versus nondeficit sub-
type,12,32e34 is not sufficient to clarify the heterogeneity,
probably because dichotomy is an oversimplifying approach
and the timing for assessing symptomatology is not well
addressed. Garver et al.35 has subtyped schizophrenia
based on patients’ differential response to antipsychotic
treatment. The “dopamine psychosis” is characterized by
rapid response to antipsychotic treatment, good growth
hormone response to apomorphine challenge, and higher
baseline plasma homovanillic acid levels.36 Patients
with delayed antipsychotic response might be a subtype
equivalent to the “neurodevelopmental psychosis”,37e40
and patients with poor treatment response is likely
a “neurodegenerative psychosis” characterized by progres-
sively degenerating processes.41 Such a hypothetical
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272 C.-C. Liu et al.psychopharmacologic-oriented trichotomy warrants further
examinations by other measurements, and our clinical
observations possibly revealed an equivalent model.
Subtyping at 6 months after an acute episode provides
a relatively stable categorization across a span of 5 years.
The PDH group was at the highest risk to have worsened
symptom dimensions (except the negative symptom) and to
have poorer social functioning; they also had the worst
neuropsychologic performance. The MB group was at the
highest risk of having worse negative symptom scores and
a higher risk of poorer disorganization scores than the RM
group; they tended to maintain an intermediate level of
social functioning in comparison with the other two groups.
The RM group had the best chance to maintain favorable
profiles in all symptom dimensions, social functioning, and
neuropsychologic performance throughout the course.
Such a subtyping strategy could also be indirectly sup-
ported by the differences in patients’ clinical features at
recruitment. The PDH group had the earliest age at onset,
received the highest CPZE during hospitalization, and had
the longest duration of hospitalization; the MB group
received a dosage similar to that of the PDH group, yet
the MB group had the highest baseline negative symptom
scores; the RM group had the oldest age at onset, the
lowest CPZE, and the shortest duration of hospitalization.
To validate the applicability of the GAP method, we need to
test it with another group of schizophrenic patients and to
transform our statistical measures to nominate classifica-
tion at individual levels.
There are a few important limitations to address in this
study. The attrition rates ranged from 10% to 25% annually,
an extent comparable to a similar longitudinal study.42
Thus, we might have excluded patients with very good and
very poor outcomes.43 Although the effects of missing
pattern on PANSS profiles in the first 2 years were not
noticeable between 2-year completers and the missing, the
interpretation of 5-year analysis results should be conser-
vative. The relatively small number of first episode (FE)
patients (62 at recruitment) and attritions (34 at 5-year
follow-up) do not allow us to investigate this important
factor on outcomes in detail. Adjusting for subtypes, we
only found that the FE group had better interpersonal
relationships and family life during follow-up, yet failed to
demonstrate differences in symptomatology and neuro-
psychologic tests compared with the non-FE patients. Our
measurement of social functioning, a self-report scale
with four highly correlated domains, limits our ability to
extrapolate our findings to broader aspects of social func-
tioning, such as rehospitalization, days at work, income,
substance abuse, and crime.44 We failed to show differences
between the MB and the RM in neuropsychologic tests
possibly because we measured it relatively late in the
course, because studies have suggested that neurocognitive
deficits might exist early at the onset of schizophrenia, even
for good responders, and remain quite stable throughout
the course.45e47 As negative symptoms, attention, verbal
memory, and memory were found to affect patients’
psychosocial functioning,48 further analyses should be done
to delineate the intertwined relationships among factors
affecting the course and outcomes of schizophrenia.44,49
The implications of this subtyping strategy can be
twofold. Clinically we can advise schizophrenic patients
Schizophrenia course by a three-subtype model 273and their caregivers not to panic or be pessimistic about an
acute state as the emergence of florid psychotic symptoms
was not necessarily linked to poor prognosis. Instead they
should actively participate in treatment during the acute
state to ensure remission as to have better outcomes.
Theoretically this three-subtype model might serve as
a framework to examine the different psychopathologic
processes regarding the heterogeneity of schizophrenia. In
the future we will use an artificial neural network to offer
convenient clinical applications,50 and use prospective
studies on FE schizophrenia with stringent follow-up, as
well as psychopharmacologic, neurobiologic, and genetic
studies to retest this three-subtype model.Acknowledgments
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